J Clin Oncol 2016 10;34(30):3609-3617
Cyrille Hulin, Bordeaux Hospital University Center, Bourdeaux; Philippe Rodon, Centre Hospitalier de Périgueux, Périgueux; Brigitte Pégourié, Centre Hospitalier Regional Universitaire, Grenoble; Laurent Garderet, Centre Hospitalier Universitaire (CHU) Hôpital St-Antoine, Paris; Isabelle Azais, CHU Institut National de la Santé et de la Recherche Médicale (INSERM); Xavier Leleu, Hôpital de la Milétrie, CHU INSERM, Poitiers; Margaret Macro, CHU de Caen, Caen; Bruno Royer, University Hospital, Amiens; Thierry Facon, Hôpital Claude Huriez, Centre Hospitalier Régional Universitaire de Lille, Lille, France; Andrew Belch, Cross Cancer Institute, Edmonton, Alberta; Chaim Shustik, Royal Victoria Hospital; Richard LeBlanc, Hôpital Maisonneuve-Rosemont, Montreal, Quebec; Kevin Song, Vancouver General Hospital, Vancouver, British Columbia, Canada; Maria Teresa Petrucci, Azienda Policlinico Umberto I, University La Sapienza, Rome, Italy; Ulrich Dührsen, University Hospital of Essen, West German Cancer Center, Essen, Germany; Jin Lu, Peking University Institute of Hematology, People's Hospital, Beijing, China; Hannah Hunter, Derriford Hospital, Plymouth, United Kingdom; Richard Eek, Border Medical Oncology, Wodonga, Victoria, Australia; Heinz Gisslinger, Medizinische Universität Wien, Vienna, Austria; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Cristina Goncalves, Hospital de Santo Antonio-Porto, Porto, Portugal; Ken Romeril, Wellington Hospital, Wellington, New Zealand; Chantal Doyen, Université Catholique de Louvain (UCL), CHU UCL Namur, Yvoir; Fritz Offner, Universitair Ziekenhuis Gent, Ghent, Belgium; Nicolas Leupin, Celgene International, Boudry, Switzerland; Vanessa Houck, Guang Chen, and Annette Ervin-Haynes, Celgene, Summit, NJ; and Meletios A. Dimopoulos, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.